The Evolving Landscape: Integrating Skin Cancer Screening Into Primary Care
June 26th 2025Panelists discuss the vital role of primary care providers in early skin cancer detection, highlighting the need for improved diagnostic confidence, integration of artificial intelligence (AI) tools, and efficient workflows to overcome time and resource constraints, ultimately aiming to reduce delays and improve patient outcomes.
A Visible Disease with Invisible Pain: Mona Shahriari Discusses Suicide Risk in Atopic Dermatitis
June 25th 2025Dermatologists aren't trained in mental health but once in practice they need to have a deep appreciation for the emotional impact of diseases like AD and a low bar for mental health referral.
Johann Gudjonsson, MD, PhD, on Emerging AD Therapies: From Single Targets to Combination Approaches
June 19th 2025RAD 2025: Johann Gudjonsson, MD, PhD, on investigational AD treatments, including anti–IL-31 receptor antibodies, anti–IL-13 treatments, IL-4 receptor blockers, JAK inhibitors, and new topical agents.
Transitioning to the Real-World: Expert Experiences with Nasal Epinephrine Spray
June 10th 2025A panelist discusses how shared decision-making between healthcare providers and patients should guide epinephrine device selection, with two real-world case studies demonstrating successful Neffy use in treating anaphylaxis with rapid symptom resolution.
A Fit for Many: Storage, Shelf Life, and Ideal Patients
June 10th 2025A panelist discusses how Neffy addresses unmet needs through superior temperature stability (tolerating up to 122°F for 3-4 days), extended shelf life (24-30 months), and needle-free administration that eliminates injection-related complications.
Safety Solidified: Results of Oral Food Challenge Trials With Nasal Epinephrine Spray
June 10th 2025A panelist discusses how real-world studies in Japan showed Neffy successfully treated grade 2 anaphylaxis symptoms in pediatric patients with a median resolution time of 16 minutes and minimal adverse effects.
Immediate Impact: Nasal Epinephrine Spray After Allergen Challenge
June 10th 2025A panelist discusses how FDA bracketing studies demonstrated that Neffy's pharmacokinetics and pharmacodynamics fall within the established safety and efficacy range of existing epinephrine auto-injectors, with rapid onset within one minute.
Nasal Epinephrine Spray: Review of Clinical Trial Results
June 10th 2025A panelist discusses how Neffy represents a novel intranasal epinephrine delivery system using three FDA-approved components: epinephrine, Intravail absorption enhancer, and a proven nasal spray device already used in other medications.
An Opportunity for Innovation: Rethinking Unmet Needs in Epinephrine Administration
June 10th 2025A panelist discusses how multiple barriers prevent timely epinephrine use, including patient reluctance to use auto-injectors, lack of device availability, uncertainty about administration timing, and cost concerns, leading to widespread underuse.
Bridging the Barriers: What is Preventing Patients From Using Epinephrine
June 10th 2025A panelist discusses how early epinephrine administration significantly reduces severe complications, prevents progression to life-threatening stages, and decreases the need for additional medical interventions like hospitalization or multiple doses.
Epinephrine First: The Proven First-Line Treatment for Anaphylaxis
June 10th 2025A panelist discusses how epinephrine is the first and only evidence-based first-line treatment for anaphylaxis, working through alpha and beta adrenergic receptors to rapidly reverse life-threatening symptoms unlike slower-acting antihistamines.